Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen, one of the largest biotechnology companies in the world, delivered a solid fourth-quarter earnings beat in both top and bottom line numbers as well as issued solid guidance for 2025, but some ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

However, Amgen’s forward revenue guidance may also be behind the stock’s post-earnings slide. The company expects revenue to ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...